FDA Approves Moderna’s mRNA Flu Vaccine for Adults 50 and Older
The FDA has approved Moderna's mRNA seasonal flu vaccine, mFLUSIVA, which will be available for individuals aged 50 and older starting with the 2026-2027 respiratory illness season.
Houston, TX, August 6, 2026 —
The U.S. Food and Drug Administration (FDA) has granted approval for Moderna’s messenger RNA (mRNA) seasonal flu vaccine, branded as mFLUSIVA. This new vaccine is designated for use in individuals aged 50 years and older.
mFLUSIVA is set to become available for the 2026-2027 respiratory illness season. The approval marks a significant development in vaccine technology, bringing mRNA capabilities to seasonal influenza prevention for a specific adult demographic.
Further details regarding the vaccine’s efficacy, specific clinical trial outcomes, and distribution plans were not immediately available.
Story summarized from the original created by KTRKWWWgeneral@email.disney.com(KTRK-TV Houston) on abc13.com, see more information here.
